Hepatitis C and steatosis: A reappraisal

Journal of Viral Hepatitis

Volumn 13, Issue 2, 2006, Pages 73-80

  Lonardo, A ^a,b   Loria, P ^b   Adinolfi, L E ^c   Carulli, N ^b   Ruggiero, G ^c  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Fibrosis; Hypobetalipoproteinaemia; Natural history; Treatment

Indexed keywords

ANTIVIRUS AGENT; CHOLESTEROL; INTERFERON; PEGINTERFERON; RIBAVIRIN;

BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 3; HUMAN; HYPOBETALIPOPROTEINEMIA; HYPOCHOLESTEROLEMIA; LIVER CELL CARCINOMA; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN;

ANTIVIRAL AGENTS; BODY MASS INDEX; CHOLESTEROL; FATTY LIVER; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPOBETALIPOPROTEINEMIAS; LIVER CIRRHOSIS; PREVALENCE; SPECIES SPECIFICITY;

EID: 33645097198     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00669.x     Document Type: Review

References (64)

1. Monto A Hepatitis C and steatosis Semin Gastrointest Dis 2002 13 40 46
2. Poynard T Ratziu V McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and Ribavirin on steatosis in patients infected with hepatitis C Hepatology 2003 38 75 85
3. Ratziu V Trabut JB Poynard T Fat, diabetes, and liver injury in chronic hepatitis C Curr Gastroenterol Rep 2004 6 22 29
4. Lonardo A Adinolfi LE Loria P Carulli N Ruggiero G Day CP Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease Gastroenterology 2004 126 586 597
5. Cholet F Nousbaum JB Richecoeur M et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients Gastroenterol Clin Biol 2004 28 272 278
6. Heathcote J Weighty issues in hepatitis C Gut 2002 51 7 8
7. McCullough AJ Obesity and its nurturing effect on hepatitis C Hepatology 2003 38 557 559
8. Negro F Hepatitis C and liver steatosis: when fat is not beautiful J Hepatol 2004 40 533 535
9. Ebeling F Epidemiology of the hepatitis C virus Vox Sang 1998 74 Suppl. 2 143 146
10. Powell EE Edward-Smith CJ Hay JL et al Host genetic factors influence disease progression in chronic hepatitis C Hepatology 2000 31 828 833
11. Hoofnagle JH Course and outcome of hepatitis C Hepatology 2002 36 S21 S29
12. Seef LB Natural history of chronic hepatitis C Hepatology 2002 36 S35 S46
13. Falck-Ytter Y Kale H Mullen KD Sarbah SA Sorescu L McCullough AJ Surprisingly small effect of antiviral treatment in patients with hepatitis C Ann Intern Med 2002 136 288 292
14. Scheuer PJ Ashrafzadeh P Sherlock S Brown D Dusheiko GM The pathology of hepatitis C Hepatology 1992 15 567 571
15. Fiore G Fera G Napoli N Vella F Schiraldi O Liver steatosis and chronic hepatitis C. A spurious association Eur J Gastroenterol Hepatol 1996 8 125 129
16. Czaja AJ Carpenter HA Santrach PJ Moore SB Host- and disease-specific factors affecting steatosis in chronic hepatitis C J Hepatol 1998 29 198 206
17. Hourigan LF Macdonald GA Purdie D et al. Fibrosis in chonic hepatitis C correlates significantly with body mass index and steatosis Hepatology 1999 29 1215 1219
18. Adinolfi LE Utili R Ruggiero G Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients Hepatology 1999 30 1530 1531
19. Fujie H Yotsuyanngi H Morija K et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis J Med Virol 1999 59 141 145
20. Rubbia-Brandt L Leandro G Spahr L et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3 Histopathology 2001 39 119 124
21. Clouston AD Jonsson JR Purdie DM et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation J Hepatol 2001 34 314 320
22. Hwang SJ Luo JC Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation J Gastroenterol Hepatol 2001 16 190 195
23. Adinolfi LE Gambardella M Andreana A Tripodi MF Utili R Ruggiero G Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV and visceral obesity Hepatology 2001 33 1358 1364
24. Petit JM Benichou M Duvillard L et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis Am J Gastroenterol 2003 98 1150 1154
25. Monto A Alonzo J Watson JJ Grunfeld C Wright TL Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 2002 36 729 736
26. Latorre P Rubbia-Brandt L Giostra E Abid K Negro F The 4,977-base pair common deletion of mitochondrial DNA is not associated with steatosis in chronic hepatitis C patients Hepatology 2002 35 239 240
27. Hui JM Kench J Farrell GC et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection J Gastro Hepatol 2002 17 873 881
28. Akuta N Suzuki F Tsubota A et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors J Hepatol 2002 37 831 836
29. Serfaty L Andreani T Giral P Carbonell N Chazouillieres O Poupon R Hepatitis C virus hypobetalipoproteinemia: a possible mecanism for steatosis in chronic hepatitis C J Hepatol 2001 34 428 434
30. Romero-Gomez M Castellano-Megias VM Grande L et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C Am J Gastroenterol 2003 98 1135 1141
31. Asselah T Boyer N Guimont MC et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C Gut 2003 52 1638 1643
32. Ohata K Hamasaki K Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection Cancer 2003 97 3036 3043
33. Hu KQ Kyulo NL Esrailian E et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States J Hepatol 2004 40 147 154
34. Rubbia-Brandt L Fabris P Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way Gut 2004 53 406 412
35. Sharma P Balan V Hernandez J et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors Dig Dis Sci 2004 49 25 29
36. Patton HM Patel K Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients J Hepatol 2004 40 484 490
37. Zaitoun AM Al Mardini H Awad S Ukabam S Makadisi S Record CO Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C J Clin Pathol 2001 54 461 465
38. Brunt EM Nonalcoholic steatohepatitis Semin Liver Dis 2004 24 3 20
39. Rubbia-Brandt L Quadri R Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J Hepatol 2000 33 106 115
40. Ong JP Younossi ZM Speer C Olano A Gramlich T Boparai N Chronic hepatitis C and superimposed nonalcoholic fatty liver disease Liver 2001 21 266 271
41. Hofer H Bankl HC Wrba F et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a Am J Gastroenterol 2002 97 2880 2885
42. Westin J Nordlinder H Lagging M Norkrans G Wejstal R Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients J Hepatol 2002 37 837 842
43. Naeem M Bacon BR Mistry B Britton RS Di Bisceglie AM Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C Am J Gastroenterol 2001 96 2468 2472
44. Toyoda H Kumada T Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C Ann Intern Med 2000 133 921
45. Wong VS Wight DG Palmer CR Alexander GJ Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model J Clin Pathol 1996 49 465 469
46. Friedenberg F Pungpapong S Zaeri N Braitman LE The impact of diabetes and obesity on liver histology in patients with hepatitis C Diabetes Obes Metab 2003 5 150 155
47. Serfaty L Poujol-Robert A Carbonell N Chazoillieres O Poupon R Poupon R Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C Am J Gastro 2002 97 1807 1812
48. Castèra L Hézode C Roudot-Toraval F Bastie A Zafrani ES Pawltowski JM Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 2003 52 288 292
49. Hickman IJ Clouston AD Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C Gut 2002 51 89 94
50. Ryder SD Irving WL Jones DA Neal KR Underwood JC Trent Hepatitis C Study Group Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 2004 53 451 455
51. Walsh MJ Vanags DM Clouston AD et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury Hepatology 2004 39 1230 1238
52. Cortez-Pinto H Baptista A Camilo ME de Moura MC Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis Hepatogastroenterology 2001 48 87 90
53. Kumar D Farrell GC Fung C George J Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response Hepatology 2002 36 1266 1272
54. Zeuzem S Hultcrantz R Bourliere M et al. Peginterferon alfa-2b plus Ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 2004 40 993 999
55. Manns MP McHutchison JG Gordon SC et al. Peginterferon alfa-2b plus Ribavirin compared with interferon alfa-2b plus Ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001 22 358 958 965
56. Castera L Hezode C Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis Gut 2004 53 420 424
57. Craxi A Licata A Clinical trial results of peginterferons in combination with Ribavirin Semin Liver Dis 2003 23 Suppl. 1 35 46
58. Bahtiyar G Shin JJ Aytaman A Sowers JR McFarlane SI Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights Curr Diab Rep 2004 4 194 198
59. Petit JM Bour JB Galland-Jos C et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C J Hepatol 2001 35 279 283
60. Hui JM Sud A Farrell GC et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology 2003 125 1695 1704
61. Bugianesi E Zannoni C Vanni E Marzocchi R Marchesini G Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship Dig Liver Dis 2004 36 165 173
62. Zhu AX Chung RT Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma Cancer 2003 97 2948 2950
63. Hickman IJ Jonsson JR Prins JB et al Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Gut 2004 53 413 419
64. Bellentani S Saccoccio G Costa G et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group Gut 1997 41 845 850